This role serves as a key business partner across Clinical Trial Management, Clinical Data Sciences, Clinical Systems, Biosample Operations, and other cross-functional team members to drive operational excellence, portfolio visibility, resource planning, performance measurement, and process optimization. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition.